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Abstract 30 
The intestinal microbiota plays an important role in health, particularly in promoting intestinal 31 
metabolic capacity and in maturing the immune system. The intestinal microbiota also 32 
mediates colonization resistance against pathogenic bacteria, hence protecting the host from 33 
infections. On the other hand, some bacterial pathogens deliver toxins that target 34 
phylogenetically related or distinct bacterial species in order to outcompete and establish 35 
within the microbiota. The most widely distributed weapons include bacteriocins, as well as 36 
contact-dependent growth inhibition and type VI secretion systems. In this review, we discuss 37 
important advances about the impact of such antibacterial systems on shaping the intestinal 38 
microbiota.  39 
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The intestinal microbiota: our best frenemy 40 
The mammalian intestine is inhabited by a large and diverse community of microbes, 41 
referred to as the gut microbiota. The human gut microbiota, also referred to as a "microbial 42 
organ", weights 1-2 kg, and consists of approximately 100 trillion (1014) bacteria representing 43 
6-10 phyla, including two predominant phyla – Bacteroidetes and Firmicutes –, and about 44 
500-1000 distinct species [1]. This highly complex microbial community (see Glossary) is 45 
controlled by various factors, such as host genetics and environmental factors. Moreover, 46 
microbiota diversity and composition is influenced by host diet as well as by positive and 47 
antagonistic interactions between bacteria within the microbiota. 48 
The intestinal microbiota has an overall beneficial impact on its host, by providing 49 
metabolic activities within the intestine and favoring the development of the intestinal 50 
immune system [2] (Figure 1). Exemplifying this notion is the observation that the immune 51 
responses in mice housed in germ-free conditions are abnormal compared to conventionally-52 
colonized mice [3, 4]. Therefore, early exposure to microbes in the intestine is a critical factor 53 
to modulate intestinal immune responses [5], and a well-documented example of a single 54 
microbial member playing a central role in shaping the intestinal immune system is 55 
segmented filamentous bacteria (SFB), which can promote the robust differentiation of Th17 56 
cells [6-8]. Moreover, if not well managed, the gut microbiota can become deleterious, for 57 
example by inducing uncontrolled intestinal inflammation. In light of the benefits the 58 
microbiota confers and on its potential to harm its host, the gut microbiota has previously 59 
been referred as the host’s best frenemy [9]. 60 
Collectively, the microbiota and its derived metabolites are critical components for the 61 
maturation of host intestinal immunity, and research has accumulated on the central role 62 
played by the intestinal microbiota in the protection of the host intestine against pathogens, a 63 
phenomenon called colonization resistance [10-12]. Bacterial competition occurs either by 64 
depleting nutrients from the milieu (exploitation competition) or by deploying antibacterial 65 
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weapons to specifically eliminate target cells (interference competition) (Figure 1). Many 66 
bacteria can directly prevent intestinal pathogens colonization or overgrowth by consuming 67 
common limited resources, hence inducing starvation of competing pathogens. One example 68 
highlighting this mechanism of exploitation competition is the finding that the commensal 69 
Bacteroides thetaiotaomicron consumes carbohydrates used by the pathogen Citrobacter 70 
rodentium, thus leading to a competitive exclusion of the pathogen from the intestine [13, 14] 71 
(Figure 1). Through the production of specific metabolites, the intestinal microbiota can also 72 
modify the host environmental conditions, then compromising pathogen growth and/or 73 
virulence. Butyrate, a short-chain fatty acid (SCFA) produced by the intestinal microbiota, 74 
downregulates the expression of several virulence genes of Salmonella enterica serovar 75 
Enteritidis (S. Enteritidis) and Typhimurium (S. Typhimurium) [15] and inhibits the growth of 76 
enterohemorrhagic Escherichia coli (EHEC) [16] (Figure 1). Finally, members of the 77 
microbiota can affect the growth of other cells by producing and releasing inhibitory 78 
substances, such as antibiotics and peptide antibiotics, or by injecting antibacterial effectors 79 
into target cells. Here we will briefly describe the various mechanisms evolved by bacteria to 80 
destroy rivals and we will review recent studies on how these systems contribute to reshaping 81 
bacterial communities in vivo. 82 
  83 
Bacterial weapons in the intestine 84 
To combat competitors, bacteria deploy a broad arsenal of antibacterial weapons. 85 
These weapons vary in terms of mechanism of action, toxin targets, and mode of penetration, 86 
and hence limit the acquisition of mechanism of resistance by competitors. The most widely 87 
distributed weapons in Enterobacteria are microcins and bacteriocins [17], contact-dependent 88 
growth inhibition (CDI) [18] and Type VI secretion systems (T6SS) [19] (Figure 2). Other 89 
mechanisms, such as Type I, Type IV and Type VII secretion systems or outer membrane 90 
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exchange, have also been recently shown to mediate toxin delivery into competitors or to 91 
promote contact-dependent killing [20-25]. 92 
Bacteriocins are a group containing a large variety of proteinaceous antibiotics of 93 
various lengths: microcins are 15-60 amino-acid peptides, lantibiotics are peptide containing a 94 
modified amino-acid (lanthionine), whereas colicin-like proteins are > 40 kDa multidomain 95 
proteins and tailocins are high molecular weight multiprotein complexes resembling 96 
bacteriophage tails [26-29]. Bacteriocins are produced upon stress conditions, and share a 97 
similar mechanism of action. After release, they bind to an outer membrane receptor and 98 
parasitize cell envelope components for penetration [26, 27, 30] (Figure 2). The exploitation 99 
of specific reception and translocation machineries restrict the action of these toxins to the 100 
same or phylogenetically related species. Cell toxicity is conferred by pore-forming activity 101 
that collapses the membrane potential at the inner membrane, by digestion or cleavage of 102 
nucleic acids or of cell wall precursors [26, 30]. Bacteriocins include S-type pyocins liberated 103 
by Pseudomonas species, and colicins that are produced by enteric strains such as E. coli, C. 104 
rodentium and Enterobacter species [26, 30]. 105 
By contrast to bacteriocins that are diffusible toxins, CDI and T6SSs are cell-cell 106 
contact-dependent mechanisms. CDI is a variant of two-partner secretion, a family of Type V 107 
secretion systems widely represented in Proteobacteria [31-33]. It comprises two proteins: the 108 
CdiB outer membrane transporter translocates the CdiA protein to the cell surface. CdiA are 109 
usually elongated spring-like β-helical structures that carry a C-terminal toxin domain. The C-110 
terminal domain mediates target cell recognition, penetration and toxicity (Figure 2). Similar 111 
to bacteriocins, the requirements for specific receptors and target cell factors restrict the 112 
action of CDI to close relatives [18, 31, 34, 35]. 113 
T6SS is a more complex machinery, broadly distributed in Proteobacteria and 114 
Bacteroidetes. Its assembly requires at least 13 components to form a speargun-like weapon 115 
[19, 36, 37]. T6SS could be considered as a bacteriophage-like contractile tail structure 116 
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anchored to the cell envelope [19, 38, 39]. The tail is constituted of an effector-loaded syringe 117 
wrapped by the sheath that is built under a metastable, extended conformation [19, 36, 37, 40-118 
42]. Contraction of the sheath presumably propels the syringe towards the rival cell, and thus 119 
delivers effectors to cause cell damages [40, 42-46] (Figure 2). How the target cell is sensed 120 
and how cell-cell contact triggers T6SS assembly or firing is largely unknown but in certain 121 
cases, transcriptional, post-transcriptional or post-translational regulatory cascades, cell-122 
envelope damage or the presence of kin cell components in the milieu trigger a T6SS 123 
response to attacks [44, 46-52]. By contrast to bacteriocins and CDI, T6SSs do not exploit 124 
specific receptors, and hence target a broader range of bacteria, although no T6SS-dependent 125 
damages of Gram-positive bacteria have been observed [53]. T6SS antibacterial effectors 126 
include peptidoglycan-acting enzymes (amidases, glycosyl hydrolases), membrane-targeting 127 
proteins (phospholipases and pore-forming), nucleases and NAD(P)(+) glycohydrolases [53-128 
59]. Interestingly, the T6SS is also capable of delivering effectors into eukaryotic cells, 129 
including single-celled microorganisms and animal tissues [54, 60]. Phospholipases and 130 
nucleases can act as trans-kingdom effectors, but specialized toxins, such as those interfering 131 
with cytoskeleton or tubule dynamics, have been identified and characterized [60-67].  132 
For all these systems, attacker bacteria are protected from self-intoxication and 133 
intoxication by kin cells by the production of immunity proteins that usually bind with high 134 
affinity and inhibit the catalytic activity of the cognate effector [26, 31, 34, 54, 55, 68, 69]. 135 
In addition, some enteric pathogens can produce broadly bioactive small molecules 136 
such as antibiotics, non-ribosomal peptide antibiotics, sactibiotics and lantibiotics [70-72], 137 
that may act toward other members of the intestinal microbiota and/or toward enteric 138 
pathogens. Finally, other extracellular contractile injection systems such as R-pyocins, anti-139 
feeding prophages (Afp) and Afp-like particles have antibacterial or antimicrobial activities 140 
[73-75].  141 
! 7!
Although the role of these systems in antibacterial competition is well documented in 142 
vitro, studies have only begun to investigate their contribution in in vivo animal models. 143 
 144 
Role of bacterial competition in the intestinal microbiota  145 
The gut microbiota is a very stable ecosystem [1]. However, the invasion or 146 
overgrowth of pathogens induces dysbiosis, an instability that may alter the composition of 147 
the microbiota but also host physiology [11, 76-78]. It is now well appreciated that 148 
interference competition between members of the microbiota, in addition to indirect 149 
competition such as exploitation competition, plays a central role in microbiota ecology [78].  150 
Until recently, the role of interbacterial competition in shaping bacterial communities 151 
has been underestimated [79]. However, antibacterial weapons are key players in the control 152 
of bacterial populations, and a summary of known examples of in vivo bacterial competition 153 
is presented in Table 1. The importance of these weapons in vivo is supported by the 154 
estimation that more than 109 T6SS firing events occur per minute per gram of colonic 155 
contents [80]. T6SS gene clusters are highly represented in Bacteroidales strains, which 156 
account for a large portion of the gut microbiota [81, 82]. In addition, many Gram-negative 157 
enteric pathogens, including Vibrio cholerae, S. Typhimurium, C. rodentium, and Shigella 158 
sonnei utilize functional T6SSs to fire against other species in vitro [83, 84]. In agreement 159 
with the concept that T6SSs are important players in bacterial competition within the 160 
intestine, a number of enterobacterial T6SS gene clusters are upregulated in conditions 161 
encountered in the gut or when a threshold of cell density is reached [85]. The V. 162 
cholerae T6SS is activated by mucins and microbiota-modified bile salt [86]; the S. 163 
Typhimurium T6SS is activated by bile salts [87]; and the enteroaggregative E. coli Sci-1 164 
T6SS is responsive to iron starvation [88].  165 
V. cholerae, S. Typhimurium and S. sonnei deploy their T6SSs to kill or displace 166 
commensal bacteria, allowing a successful colonization of the host and an increased 167 
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persistence in experimental models [89-92]. Using transposon insertion site sequencing (Tn-168 
Seq) to identify V. cholerae mutants that exhibit a colonization defect in the rabbit intestine, 169 
Fu et al. found tsiV3, encoding immunity to the T6SS VgrG3 peptidoglycan hydrolase 170 
effector [93]. Interestingly, a recent study demonstrated that V. cholerae T6SS-mediated 171 
colonization specifically occurs in intestinal microenvironments, such as the middle small 172 
intestine, suggesting that T6SS effectors might target specific species [94]. The antagonistic 173 
behavior of V. cholerae in the gut triggers intestinal colonization, virulence gene expression, 174 
and host innate immune response [95]. In a recent study, Sana and collaborators demonstrated 175 
that the successful establishment of S. Typhimurium in the mouse intestine requires the T6SS 176 
Tae4 amidase effector [87]. Thus, the observation that bacterial-specific effectors are required 177 
for efficient colonization demonstrates that the T6SS mediates antagonistic interbacterial 178 
interactions during infection. It is not yet known whether T6SS specifically targets certain 179 
species, but the observation that S. Typhimurium targets Klebsiella oxytoca and has only 180 
weak impact on other species suggests that the T6SS does not fire randomly [87]. 181 
Interestingly, S. Typhimurium and K. oxytoca utilize the same carbon sources and thus the 182 
specific elimination of a metabolic competitor may provide a better access to the available 183 
nutritional resources [79]. Another example of T6SS-mediated metabolic competition is the 184 
secretion of manganese- and zinc-scavenging enzymes by pathogens such as Burkholderia 185 
thailandensis [96, 97]. In addition, EHEC uses its T6SS to secrete catalases, thus providing a 186 
higher resistance to reactive oxygen species produced by the host [98]. A recent example of 187 
the importance of the T6SS in intestinal colonization is related to the increased prevalence of 188 
S. sonnei infections over that of the close relative Shigella flexneri. By contrast to S. flexneri, 189 
the genome of S. sonnei encodes a functional T6SS that confers a competitive advantage by 190 
outcompeting S. flexneri in vitro as well as in the mouse gut [90]. Interestingly, S. sonnei also 191 
encodes the ColE1 colicin that enables E. coli elimination [90]. Those recent findings are in 192 
agreement with the observation that colicinogenic E. coli cells present an increased intestinal 193 
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persistence compared to the isogenic E. coli strain unable to produce colicins [99, 100]. Other 194 
bacteriocins and R-pyocins have the ability to destroy rivals in biofilm or mixed communities, 195 
and to specifically eliminate bacterial species after therapeutic administration; and hence are 196 
proposed to be viable alternatives to antibiotics [101-105].  197 
While the above examples showed that antibacterial weapons are used by pathogens to 198 
colonize their hosts, the gut microbiota also exerts an important control to prevent 199 
colonization by pathogens [106, 107]. Indeed, many commensal strains produce those 200 
weapons and therefore protect the niche against the invasion of external microbes or against 201 
the overgrowth of indigenous pathogens. An elegant example is the recent observation that 202 
the probiotic strain E. coli Nissle uses microcins M and H47 to limit the expansion of 203 
competing Enterobacteriaceae, including pathogens such as adherent-invasive E. coli (AIEC) 204 
and S. Typhimurium during intestinal inflammation [108]. Another example is Bacillus 205 
thuringiensis, a bacterium able to secrete a bacteriocin (thuricin CD) that directly targets 206 
spore-forming Bacilli and Clostridia, including Clostridium difficile [109]. 207 
Other commensals, such as those of the Bacteroidales order, antagonize gut microbiota 208 
using secreted antimicrobial proteins or T6SS [56, 110-113]. Interestingly, it has been shown 209 
that intense transfer of genetic material occurs between Bacteroidales species in the gut [82]. 210 
As a consequence, Bacteroidales have accumulated genes encoding immunity proteins to 211 
T6SS effectors they do not encode [80], and thus maintain a stable balance in the microbiota 212 
by preventing their own elimination. In addition, the symbiotic Bacteroides fragilis strain was 213 
shown to use the T6SS to harm enterotoxigenic B. fragilis cells, demonstrating that the 214 
activity of Bacteroidales T6SSs may protect the host against intestinal inflammatory diseases 215 
[114].  Altogether, these data demonstrate that a broad range of competitive mechanisms 216 
occurs within the intestinal microbiota and plays a role in microbiota composition, 217 
establishment, stability, and evolution. 218 
 219 
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Concluding Remarks 220 
 Future studies will be needed to further characterize mechanisms by which bacteria 221 
compete within the intestinal tract, with a particular focus on long-lasting consequences on 222 
microbiota composition and host physiology (see Outstanding Questions). Long-term 223 
experiments are also required to understand the real contribution of antibacterial weapons in 224 
shaping microbial communities. At present, it is not clear whether being well armed 225 
represents a true advantage, as antibacterial weapons have limited impact on well-structured 226 
communities [115]. In addition, microbial communities are subjected to a rock-paper-scissor 227 
game, in which the production of these weapons is energetically consuming, and hence 228 
attacker cells might be defeated by professional cheaters or by strains with a better fitness 229 
[116, 117]. 230 
 Another important field of research that needs further investigation is the impact that 231 
such antimicrobial systems may have on both microbiota composition and host physiology in 232 
the long term. An example highlighting the importance of interbacterial competition in long 233 
term dysbiosis is the observation that intestinal colonization of AIEC, an E. coli pathovar 234 
associated with Crohn’s disease, causes alteration of microbiota composition and chronic 235 
colitis in mice, with both phenotypes persisting well beyond AIEC clearance [118]. Hence, in 236 
addition to their own virulence potential, AIEC bacteria are able to induce chronic 237 
inflammation by detrimentally altering the intestinal microbiota composition [118]. While the 238 
precise role played by antibacterial systems in such long-term alterations still needs to be 239 
investigated, they may further highlight the unappreciated importance of such 240 
bacteria/bacterial competition in microbiota stability and host physiology. 241 
Finally, such antibacterial mechanisms may be tailored in a near future as an 242 
alternative or complementary approach to the use of antibiotics. A few bacteriocins, such as 243 
nisin, have been validated by the FDA and are used as food preservatives [119]. While such 244 
compounds are used to extend shelf life, we still ignore their impact on the intestinal 245 
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microbiota. In addition, colicins, R-pyocins, CdiA and T6SS effectors are modular proteins 246 
and hence might be genetically engineered to specifically target bacterial populations of 247 
interest. Modified colicins, R-pyocins or T6SS effectors have already been demonstrated to 248 
be efficiently delivered into target cells or to destroy specific species without affecting the gut 249 
microbiota diversity [87, 95, 120-124]. One may predict that these initial attempts will be 250 
actively pursued to deliver toxins or CRISPR/Cas system into specific species, with the 251 
ultimate goal to prevent intestinal colonization or to beneficially reshape an altered microbial 252 
ecosystem. 253 
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Glossary 534 
Dysbiosis: microbial population with an imbalanced composition, often associated with 535 
deleterious impact for the host. Dysbiosis has been identified as an important player of 536 
inflammation in inflammatory bowel diseases. 537 
 Intestinal immune system: The complex population of cells and interactions inhabiting our 538 
intestine with the dual role of tolerance toward our commensal microbiota and protection 539 
against intestinal pathogen. Importantly, the intestine represents the largest compartment of 540 
the immune system, with the estimation that 70% of the mammalian immune system is hosted 541 
within the intestine. 542 
Microbial community: mixed population of bacteria and single-cell microorganisms. 543 
Microbial communities include microbiota, but also biofilms (bacteria that adhere to a 544 
support) and consortiums (bacteria that exchange metabolic contents). 545 
  546 
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Legend to Figures 547 
Figure 1. Commensal microbiota-mediated colonization resistance in the intestine. The 548 
intestinal microbiota plays a central role in both intestinal barrier maintenance and immune 549 
system maturation. Examples of microbiota-mediated inhibition of intestinal colonization by 550 
enteric pathogens are represented: exploitation competition (utilization of nutrient resources), 551 
and interference competition (production of virulence gene repressor molecules or 552 
antibacterial weapons). EHEC, enterohaemorrhagic Escherichia coli. 553 
 554 
Figure 2. The arsenal of antibacterial weapons. The major antibacterial weapons used by 555 
enteric bacteria and their mechanism of action are schematically represented. Bacteriocins 556 
(green) are diffusible multi-domain proteins that are produced and released by the attacker 557 
cell. The reception (R) domain binds to the specific receptor and the translocation (T) domain 558 
helps the translocation of the activity (A) domain into the target. Contact-dependent growth 559 
inhibition (CDI, orange) comprises the CdiB translocator and CdiA toxin. The CdiA C-560 
terminal domain (Ct) binds to a specific receptor and translocates to the target cell. Type VI 561 
secretion system (T6SS, blue) is an injection system that uses a contractile mechanism to 562 
propel an effector-loaded needle into the target.  563 
  564 
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Table 1. Summary of known in vivo bacterial competition. 565 
 566 
 567 
Bacterium Weapon Target cell Toxin / Activity Reference 
Salmonella 
enterica 
Typhimurium 
T6SS Klebsiella oxytoca Tae4 (amidase) [87] 
Bacillus 
thuringiensis 
Bacteriocin 
thuricin CD 
Spore-forming Bacilli and Clostridia, 
including C. difficile pore-forming [109] 
Burkholderia 
thailandensis T6SS unknown unknown [96, 97] 
EHEC T6SS - Catalases [98] 
Shigella sonnei T6SS S. flexneri Unknown [90] 
Shigella sonnei ColE1  colicin E. coli Pore-forming [90] 
E. coli Nissle Microcins M and H47 
Enterobacteriaceae, including 
pathogens such as AIEC and S. 
Typhimuirum 
unknown [108] 
Bacteroides 
fragilis T6SS 
B. fragilis, gut microbiota and 
pathogenic bacteria Bte2 
[56, 110, 
114] 
V. cholerae T6SS commensal E. coli unknown [95] 
Outstanding Questions Box 
 
- How do antibiotics and antibacterial molecules alter the intestinal microbiota composition 
and affect colonization resistance? 
- What are the direct impacts of antibacterial weapons in the gut? 
- What is the contribution of the antibacterial weapons of commensals in the protection of the 
host against pathogens? 
- What is the target range of T6SS and what is the cost to produce antibacterial weapons? 
- Is it a real benefit for the bacterium to be equipped with antibacterial weapons? 
- How can antibacterial weapons be genetically modified for therapeutic purposes in order to 
manipulate the intestinal microbiota in beneficial ways?  
- What are the long term impacts of such antibacterial systems on the microbiota community 
and host physiology?!
Trends Box 
- The intestinal microbiota is a complex but stable ecosystem that plays a central role in 
human health, and disturbance of its composition and function is associated with many 
diseases. 
- Within the intestinal microbiota, bacteria exchange material and information. 
- The microbiota can be peaceful, but many bacteria fight with others to have a better access 
to their niche or nutrients. 
- Different antibacterial weapons have been identified and characterized, and many bacterial 
pathogens use these weapons to establish themselves in the intestinal environment, whereas 
some commensals use these weapons to specifically target pathogens, leading to protection of 
the host. !


